Abstract
Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 547-550 |
| Number of pages | 4 |
| Journal | Current pharmaceutical design |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 1 2017 |
Keywords
- Age-related eye disease study (AREDS)
- Age-related macular degeneration (AMD)
- Age-related maculopathy susceptibility 2 (ARMS2)
- Complement factor H (CFH)
- Pharmacogenetics
- Vascular endothelial growth factor (VEGF)
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery